Brief: Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data From Phase 3 Study Of Omidubicel
27/04/2022 12:05
April 27 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL PRESENTS UPDATED ONE-YEAR POST-TRANSPLANT FOLLOW UP DATA FROM
PHASE
3 STUDY OF OMIDUBICEL AT 2022 TRANSPLANTATION & CELLULAR THERAPY MEETINGS OF
ASTCT AND CIBMTR TANDEM MEETINGS
Source text for Eikon: ID:nBw3p1Mrya
Further company coverage: GMDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq